W1315 Evaluation of the Bristol Stool Form Scale As a Marker for GI Transit in Patients with Chronic Constipation

Aim: Little data is available regarding the effectiveness of natural foods in treating chronic constipation. We aimed to identify whether prune ameliorates chronic constipation and can be used safely for a relatively long time. Methods: In this double-blind, randomized, placebo-controlled trial, 84 subjects with chronic constipation, presenting more than 6 months before and persisting for more than 3 months, were randomized to prune (n=42) or placebo (n=42) intake for 8 weeks. We assessed daily Bristol stool form scale (BSFS) scores and stool frequencies and administered the gastrointestinal symptom rating scale (GSRS) questionnaire, as primary outcomes for constipation improvement. Results: The prune group showed significantly decreased rates of hard stool (BSFS1 or 2) and increased rates of normal stool (BSFS 3 or 4) after 1 week, which were more evident after 7 weeks between the two groups. Prune significantly increased stool frequency immediately after 1 week. Furthermore, GSRS of hard stools, flatulence, and incomplete evacuation significantly improved after 4-8 weeks of prune intake, of which constipation and hard stools were significantly reduced compared to the placebo group. In contrast, prune intake did not cause diarrhea, loose stools, or urgent need for defecation during 8 weeks evaluated by GSRS score. We found no abnormal laboratory tests of liver function, renal function, inflammation, or urinalysis after prune intake. Conclusions: Daily prune intake ameliorates chronic constipation, improving quality of life, and causes few diarrhea-related symptoms or side effects. Our results emphasize a new, useful, and easy strategy for chronic constipation. (UMIN ID:000041384)

Download Full-text

Relationship between Stool Form and Quality of Life in Patients with Chronic Constipation: An Internet Questionnaire Survey

Digestion ◽

10.1159/000502815 ◽

2019 ◽

pp. 1-8 ◽

Cited By ~ 1

Author(s):

Hidenori Ohkubo ◽

Tsutomu Yoshihara ◽

Noboru Misawa ◽

Keiichi Ashikari ◽

Akiko Fuyuki ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Constipation ◽

Questionnaire Survey ◽

Stool Form

Download Full-text

Tu2075 Comparison Between Spontaneously Reported Stool Form Using the Bristol Stool Form Scale and Stool Form Calculated From a Seven-Day Diary in Patients With Chronic Constipation

Gastroenterology ◽

10.1016/s0016-5085(13)63431-9 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-921

Author(s):

Jason Baker ◽

Shanti L. Eswaran ◽

Jennifer Rai ◽

William D. Chey

Keyword(s):

Chronic Constipation ◽

Stool Form

Download Full-text

Osteopathic Manipulative Treatment Limits Chronic Constipation in a Child with Pitt-Hopkins Syndrome

Case Reports in Pediatrics ◽

10.1155/2017/5437830 ◽

2017 ◽

Vol 2017 ◽

pp. 1-5 ◽

Cited By ~ 1

Author(s):

Alessandro Aquino ◽

Mattia Perini ◽

Silvia Cosmai ◽

Silvia Zanon ◽

Viviana Pisa ◽

...

Keyword(s):

Chronic Constipation ◽

Genetic Disorder ◽

Gastrointestinal Disorders ◽

Osteopathic Manipulative Treatment ◽

Rare Genetic Disorder ◽

Defecation Frequency ◽

Stool Form ◽

Severe Chronic Constipation

Pitt-Hopkins Syndrome (PTHS) is a rare genetic disorder caused by insufficient expression of the TCF4 gene. Children with PTHS typically present with gastrointestinal disorders and early severe chronic constipation is frequently found (75%). Here we describe the case of a PTHS male 10-year-old patient with chronic constipation in whom Osteopathic Manipulative Treatment (OMT) resulted in improved bowel functions, as assessed by the diary, the QPGS-Form A Section C questionnaire, and the Paediatric Bristol Stool Form Scale. The authors suggested that OMT may be a valid tool to improve the defecation frequency and reduce enema administration in PTHS patients.

Download Full-text

Real-world comparison of elobixibat and lubiprostone treatment in patients with chronic constipation: A propensity score matched analysis

Digestive Diseases ◽

10.1159/000512745 ◽

2020 ◽

Author(s):

Takaaki Eguchi ◽

Tetsuya Yoshizaki ◽

Seitaro Ikeoka ◽

Megumi Takagi ◽

Maho Fujinami ◽

...

Keyword(s):

Propensity Score ◽

Chronic Constipation ◽

Nearest Neighbor ◽

Japanese Patients ◽

Treatment Groups ◽

Bowel Movements ◽

Nearest Neighbor Matching ◽

Stool Form ◽

Group 2 ◽

The Individual

Introduction: Elobixibat is a new laxative, but its efficacy and adverse events (AEs) are insufficiently examined compared with those of other laxatives. Hence, by propensity score (PS) matching, we compared the effects and AEs between elobixibat and lubiprostone. Methods: We retrospectively analyzed 1887 Japanese patients with chronic constipation (CC) treated at our hospital between October 2013 and April 2020. Enrolled patients were divided into three treatment groups, namely, elobixibat (10 mg daily) (E10 group, n = 293), lubiprostone (24 mcg daily) (L24 group, n = 772), and lubiprostone (48 mcg daily) (L48 group, n = 822), as their first treatment. We then investigated the changes on the weekly average number of spontaneous bowel movements (SBMs), Stool Consistency Scores (SCSs), and AEs starting from the baseline until the end of the 2-week treatment. To adjust for patient background, we performed one-to-one nearest neighbor matching without replacement between elobixibat- and lubiprostone-treated patients according to the individual estimated PSs. Results: After treatment, for SCSs, both the L24 and L48 groups significantly improved compared with the E10 group (p < 0.05), but their stools were soft (Bristol stool form scale: 4.8). Notably, the E10 group had less frequent AEs than the L24 group (26 [9.0%] vs. 43 [14.8%], p = 0.03). Particularly, nausea was significantly less in the E10 group than in the L48 group (2 [0.7%] vs. 7 [2.4%], p = 0.01). Conclusion: Elobixibat is a beneficial drug for patients with mildly symptomatic CC and is safe to use, given its few AEs.

Download Full-text